Emerging research uncovers a hidden world of psychobiotics—gut bacteria that produce neuroactive compounds. The Institute is pioneering the study of this internal 'psychotropic pharmacy' within us all.
This post explores how indigenous plant knowledge forms the indispensable bedrock of contemporary psychopharmacology. The Institute's fieldwork bridges ancient wisdom and cutting-edge laboratory science.
Groundbreaking research at the Institute reveals the potent neuroplastic effects of classic entheogens. This work illuminates how these compounds can literally reshape neural connections, offering hope for psychiatric disorders.
The Institute was established on the principle that psychotropic substances, studied through a rigorous biological lens, hold keys to understanding consciousness. Our long-term vision bridges neuroscience, pharmacology, and ecology for holistic discovery.
Regulatory challenges delay the approval of new psychotropic treatments, varying across countries and substances.
Combining modern psychotropic treatments with traditional healing offers holistic approaches to mental health.
Addiction involves changes in brain circuits related to reward, stress, and self-control, affecting recovery.
Evaluating the safety of new psychotropic compounds involves rigorous clinical testing to identify risks and benefits.
The gut-brain axis links intestinal health to mental well-being, influenced by psychotropic drugs and microbiome.
Genetic variations influence how individuals respond to antidepressants, guiding personalized treatment plans.
The journey of psychotropics from traditional ceremonies to scientific laboratories reflects changing societal views.
Psychotropic substances can induce neuroplastic changes, influencing brain structure and function over time.
Microdosing involves taking sub-perceptual doses of psychedelics to enhance creativity, focus, and emotional balance.
Cultural attitudes toward psychotropic substances vary widely, influencing use patterns, regulations, and therapeutic acceptance.
The blood-brain barrier protects the brain but poses challenges for delivering psychotropic drugs effectively.